BPC-157

BPC-157 just got a federal advisory committee's recommendation, months after coming off a safety watchlist. Here's what actually happened in between, and what the recommendation does and doesn't mean for the vial in your fridge.

PCAC is the FDA advisory committee that reviews which raw ingredients compounding pharmacies may use. Here is what it does and what its votes mean.

BPC-157's rat data has held up for decades. Whether that mechanism does anything for the actual human joint you're injecting it into is a question a brand-new Phase 2 trial has only just started to answer.

The oral-versus-injectable debate for BPC-157 gets argued with total confidence online. The actual bioavailability data behind those arguments, in either direction, is worth checking before you pick a side.

PCAC voted to recommend BPC-157 and TB-500 for the FDA's 503A compounding list, each on its own 8-6 vote. Here's what the human trial record for each peptide shows, and where the case for stacking them turns from evidence into theory.

BPC-157, TB-500, and GHK-Cu are sold as one interchangeable injury-recovery stack, but their human evidence ranges from a real Phase 2 trial to a molecular identity gap to a null placebo-controlled result. Each is graded on its own record, not the group's pitch.

The Wolverine Stack pairs BPC-157 and TB-500 into one repair protocol — on paper a genuinely good idea: two peptides doing two different repair jobs. Here's what the pairing is meant to do for you, why the biology is exciting, and the one thing nobody has ever tested — the two of them run together.

Everyone heard "peptides are coming back." Almost nobody heard that the FDA already sat down with some of the most-stacked ones and voted no. Here's which, when, and what a July 2026 yes would actually buy you.

BPC-157 is the repair peptide half the gym is talking about. Strip out the forum noise and the answer is simple: in animals it speeds healing by growing new blood supply into injured tissue. Here is what that could mean for you, how far the human proof goes, and what the FDA is about to review.

The federal compounding framework applies the same way in every state. The state pharmacy boards do not. The result is a real state-by-state patchwork that decides whether a telehealth prescription for a compounded peptide is actually fillable where you live.

The "announcement" was a Joe Rogan appearance, not a Federal Register notice. The wellness scene heard one thing. The actual signal was narrower, and the rulemaking that turns it into access is still more than a year away.

Section 503B outsourcing facilities are the higher-volume, FDA-inspected cousin of the corner compounding pharmacy. The 503B Bulks List is its own regulatory pipeline — and it changes what an actual peptide supply chain looks like when one opens.

Two days at FDA's White Oak campus decided which of seven peptides US compounding pharmacies may eventually dispense by prescription. The recommendation is not an approval, the docket is not all the peptides, and the framing the forums used going in was mostly wrong.

Chronic, low-grade inflammation tracks with slower recovery, stiff joints, and how fast you age. Three peptides under FDA review — KPV, BPC-157, and GHK-Cu — each turn it down from a different direction. Here is what that could mean for you, and how far the human proof actually goes.

Collagen is the scaffolding under your skin, tendons, and joints — and three peptides now in front of the FDA each lean on how your body builds it. Here is what that could mean for repair and ageing, why the biology is genuinely exciting, and how far the human proof actually goes.

Most peptides come as a vial and a needle for one reason — swallow them and your gut destroys them before they can work. Understanding how a peptide actually gets into your body is the single lens that tells you whether a product can work at all. Here is how it works, in plain English.

Repair runs on fresh plumbing — new blood vessels growing into damaged tissue. It's the mechanism three of the most-talked-about recovery peptides — BPC-157, TB-500 and GHK-Cu — are built on. Here's what that could mean for how you heal, and the one question the same biology always raises.

BPC-157's reputation rests on one mechanism — it appears to build fresh blood supply into damaged tissue. Here is that mechanism in plain language, angiogenesis and nitric oxide made simple, what it could mean for recovery, how far the animal proof goes, and the FDA review set for July 2026.

BPC-157 and GHK-Cu both get sold as tissue-repair peptides, but they are tools for two different jobs — BPC-157 for deep tissue like tendon and gut, GHK-Cu for skin and surface. Here is what each could do for you, which goal each one fits, and how far the proof actually goes.

BPC-157 and TB-500 aren't two flavours of one recovery peptide — they're unrelated proteins aimed at different kinds of damage. Here is what each could actually do for you, which one fits which injury, and how far the human proof goes for both.